Group 1 - The company has reported overseas revenue of 34.44 million yuan in the first half of 2025, which accounts for 3.04% of its total revenue [2]

Core Viewpoint - The company, Jianfan Biological (300529.SZ), provided insights on its sales performance related to centralized procurement and its overseas market expansion efforts. Group 1: Centralized Procurement Impact - In 2024, the sales revenue from high-flow and low-flow blood dialysis machines through centralized procurement is projected to be 9.62 million yuan, accounting for 0.36% of the total revenue during the same period [1] - The sales revenue from blood dialysis tubing through centralized procurement is expected to be 3.36 million yuan, representing 0.13% of the total revenue [1] - For the first half of 2025, the sales revenue from high-flow and low-flow blood dialysis machines through centralized procurement is anticipated to reach 15.2 million yuan, which will be 1.34% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in the same period is projected to be 2.45 million yuan, accounting for 0.22% of the total revenue [1] - Currently, the company's main product, blood perfusion devices, has not been included in the centralized procurement scope at the national or provincial levels [1] Group 2: Overseas Market Development - In the first half of 2025, the company expects to achieve revenue of 34.44 million yuan from overseas markets, which will constitute 3.04% of the total revenue [1] - The company plans to focus on international market expansion by actively engaging in cross-border research collaborations, refining its overseas distributor network, recruiting overseas marketing personnel, and concentrating on key countries [1] - The strategy aims to tap into overseas market opportunities and drive growth in international business through a dual approach of "chronic diseases + acute critical illnesses" [1]

Core Viewpoint - The company has reported a significant reduction in sales expenses and is adjusting the pricing of its blood perfusion device in response to new healthcare policies in China [1] Group 1: Sales Expenses - In the first half of 2025, the company's sales expenses amounted to 24.961 million yuan, representing a year-on-year decrease of 26.75% [1] Group 2: Policy Impact - The National Healthcare Security Administration issued a guideline in June this year, adding "blood dialysis perfusion fee" and "plasma adsorption fee" as new items, which have been officially included in the medical insurance projects with independent pricing standards [1] - Over twenty provinces in China are actively implementing these policies, which are expected to drive growth in the clinical use of blood perfusion and adsorption products [1] Group 3: Pricing Adjustment - Starting from September 2025, the company will adjust the price of its KHA130 blood perfusion device, which is specifically used for maintenance hemodialysis patients, as part of its commitment to social responsibility and patient care [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-074 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 3、转股价格：38.65 元/股 4、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 5、根据公司《健帆生物科技集团股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）规定：在可转债存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格 低于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交 公司股东大会表决。 自 2025 年 9 月 15 日至 2025 年 9 月 26 日，公司股票已有十个交易日低于当 期转股价格的 85%。若触发转股价格修正条件，公司将按照《募集说明书》的约 定及时履行后续审议程序和信 ...

Group 1 - The core point of the article is that Jianfan Bio has announced the transfer of convertible bonds by its controlling shareholder, Dong Fan, which will take place by September 22, 2025 [2][3] - Dong Fan will transfer a total of 1,264,320 "Jianfan Convertible Bonds," representing 12.64% of the total issued convertible bonds [2]

Core Viewpoint - The company, Jianfan Bio, has announced that its controlling shareholder and actual controller, Mr. Dong Fan, will transfer 1,264,320 units of "Jianfan Convertible Bonds" by September 22, 2025, which represents 12.64% of the total issued convertible bonds [1] Group 1 - The transfer of convertible bonds is part of a planned divestment by the controlling shareholder [1] - The total amount of convertible bonds being transferred is significant, indicating a strategic move by the shareholder [1] - The transaction will take place through the Shenzhen Stock Exchange trading system [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-073 债券代码：123117 债券简称：健帆转债 二、债券持有人历次可转债持有比例变动情况 截至 2025 年 9 月 16 日，公司控股股东、实际控制人董凡先生通过深圳证券 交易所交易系统转让其所持有的"健帆转债"1,319,814 张，占本次发行可转换 公司债券总量的 13.20%。转让后董凡先生持有"健帆转债"3,037,830 张，占本 次发行可转换公司债券总量的 30.38%。具体内容详见公司 2025 年 9 月 17 日刊 载于巨潮资讯网（www.cninfo.com.cn）的《关于债券持有人可转债持有比例变 动达到 10%的公告》（公告编号：2025-072）。 公司于近日收到控股股东、实际控制人董凡先生的通知，截至 2025 年 9 月 22 日，董凡先生通过深圳证券交易所交易系统转让其所持有的"健帆转债" 1,264,320 张，占本次发行可转换公司债券总量的 12.64%，具体变动情况如下： 1 健帆生物科技集团股份有限公司 关于债券持有人可转债持有比例变动达到 10%的公告 本公司及董事会全体成员保证信息披露的内容真实、 ...

Core Viewpoint - The article emphasizes the importance of improving the quality of life for patients with uremia through innovative treatment options and social responsibility initiatives, particularly highlighting the role of Jianfan Group in this endeavor [3][14]. Group 1: Medical Innovations - Over 3 million patients globally rely on dialysis, facing challenges in self-management and treatment delays, which affect their life expectancy [1] - Jianfan Group developed the HA130 blood perfusion device in 2004, which effectively removes medium and large molecular toxins that traditional dialysis cannot, filling a significant gap in treatment options [5][6] - The company has published over 3,000 clinical papers, with more than 300 included in international journals, establishing a strong evidence base for its products [6] Group 2: Clinical Application and Standardization - Jianfan has conducted extensive clinical trials, leading to the inclusion of its blood perfusion technology in clinical standard operating procedures and expert consensus guidelines [6][7] - The combination of dialysis and perfusion has been recognized as a standard treatment option, supported by a robust training and operational guideline framework [7] Group 3: Policy and Economic Impact - Recent healthcare reforms in China have made blood purification treatments more accessible and affordable for patients, with new guidelines for dialysis perfusion services introduced by the National Healthcare Security Administration [8] - Jianfan has responded to these reforms by reducing the prices of its perfusion devices while maintaining quality, thus enhancing patient access to innovative treatments [8] Group 4: Global Expansion and Market Position - Jianfan's blood perfusion technology has gained international recognition, with products entering over 8,000 hospitals worldwide and holding a market share of over 70% in the blood perfusion sector [10] - The company has obtained CE certification for multiple products, facilitating its entry into global markets and showcasing the success of Chinese innovation in high-end medical devices [10][11] Group 5: Social Responsibility and Community Engagement - Jianfan has established a dual system for corporate social responsibility, focusing on healthcare initiatives and community support, including the establishment of "Uremia Care Day" to raise awareness [12][14] - The company aims to unite government, medical institutions, and social organizations to protect the dignity of patients, exemplified by success stories of patients regaining mobility through their treatments [12][14]

Group 1: Stock Performance and Investor Relations - The company's stock price has recently declined due to various factors, and management is considering measures such as share buybacks and stock purchases to boost investor confidence [1][2] - The company has implemented multiple strategies, including cash dividends and stock incentive plans, to enhance investor trust [2] Group 2: Project Development and Market Potential - The polyethersulfone project is currently in the R&D phase and has not yet reached mass production; future revenue projections will be disclosed in regular reports [2] - The company has been recognized by the Ministry of Industry and Information Technology and the National Medical Products Administration for its innovative biomedical materials [2] Group 3: Sales and Marketing Strategies - The company emphasizes the need for ongoing investment in sales expenses to promote new technologies and products in the clinical setting [3] - The blood purification industry is still in its early stages, necessitating significant market promotion efforts [3] Group 4: Health Management Initiatives - The company is actively exploring new business areas related to metabolic cardiovascular diseases and health management, responding to national health initiatives [4] - A major clinical study on plasma adsorption in stroke patients has been initiated, showing promising preliminary results [4] Group 5: Product Pricing and Market Impact - The blood purification products have not yet been included in centralized procurement, but there is a possibility for future inclusion, which could affect pricing and profit margins [5] - The company is preparing for potential impacts from centralized procurement policies, focusing on quality competition rather than just price [5] Group 6: Research and Development Focus - The company invests over 200 million annually in R&D, having registered 11 new products since 2022 [11] - The R&D strategy includes developing various blood purification products targeting different diseases, maintaining a competitive edge in the industry [10] Group 7: International Expansion and Market Strategy - The company is prioritizing international market expansion, having achieved product entry in 98 countries and established a presence in over 2000 hospitals abroad [18] - The focus is on academic promotion and collaboration to enhance global awareness of blood adsorption technology [18] Group 8: Regulatory and Policy Developments - Recent policy changes have officially included blood purification and plasma adsorption in the medical insurance reimbursement list, which is expected to accelerate product promotion [19] - The company is committed to timely and accurate information disclosure to protect investor rights [19]

Core Viewpoint - The company, Jianfan Bio (300529.SZ), has announced that its controlling shareholder and actual controller, Mr. Dong Fan, will transfer 1,319,814 shares of "Jianfan Convertible Bonds" through the Shenzhen Stock Exchange by September 16, 2025, which represents 13.20% of the total issued convertible bonds [1] Group 1 - The transfer of convertible bonds is part of a planned divestment by the controlling shareholder [1] - The total amount of convertible bonds being transferred is significant, indicating a strategic move by the shareholder [1] - The transaction will take place via centralized bidding on the Shenzhen Stock Exchange [1]